IP Library Granted Patent US 12,163,188
Granted Patent B2
US 12,163,188 · App. 17/935,406 · Granted Dec 10, 2024

Polymerase compositions and methods

Inventors: Stephen P. Hendricks (Los Gatos, CA); Michael Phelan (Millbrae, CA); Marian Peris (San Mateo, CA); Cheng-Yao Chen (San Diego, CA); Daniel Mazur (San Diego, CA); Xinzhan Peng (Carlsbad, CA); Amy Castillo (Houston, TX)
Assignee: Life Technologies Corporation
C12Q1/6869C07H19/20C12N9/1241C12N9/1252C12N9/96C12Q1/6818C12Y207/07007G01N21/6428G01N33/582C12Y207/07G01N2021/6432
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,163,188
App. No.
17/935,406
Granted
Dec 10, 2024
Kind
B2
Abstract

Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.

Claims (13)

1. A DNA polymerase having a photostability that is at least about 80% under standard photostability assay conditions, wherein the polymerase comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 7, further comprising an amino acid substitution selected from the group consisting of: K372G, K372T, K372S, K372R, K372A, K372Q, K372W, K372Y, K372F, wherein the numbering is relative to the amino acid sequence of SEQ ID NO: 7.

2. The DNA polymerase of claim 1 , wherein the polymerase comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO: 7.

3. The DNA polymerase of claim 1 , wherein the polymerase further comprises a mutation reducing 3′ to 5′ exonuclease activity.

4. The DNA polymerase of claim 3 , wherein the mutation reducing 3′ to 5′ exonuclease activity comprises one or more amino acid substitutions at positions selected from the group consisting of: 2, 9, 11, 12, 58, 59, 63, 162, 166, 377 and 385.

5. The DNA polymerase of claim 1 , wherein the polymerase further comprises a mutation increasing the branching ratio of the enzyme with a labeled nucleotide.

6. The DNA polymerase of claim 1 , wherein the polymerase further comprises a mutation increasing the primer extension activity.

7. The DNA polymerase of claim 6 , wherein the mutation increasing the primer extension activity comprises one or more amino acid substitutions selected from the group consisting of: 129 and 339.

8. The DNA polymerase of claim 1 , wherein the polymerase further comprises a mutation increasing the affinity of the polymerase for a particular labeled nucleotide.

9. The DNA polymerase of claim 1 , wherein the DNA polymerase has amino acid leucine at position 383 and amino acid asparagine at position 384.

10. The DNA polymerase of claim 9 , wherein the DNA polymerase exhibits increased polymerase activity relative to the unmodified reference B103 polymerase, SEQ ID NO: 6.

11. The DNA polymerase of claim 9 , further including one or more additional amino acid modifications consisting of one or more amino acid substitutions, additions or deletions at one or more positions selected from the group consisting of: 2, 9, 11, 12, 58, 59, 63, 162, 166, 377 and 385, and the DNA polymerase exhibits reduced exonuclease activity relative to an unmodified B103 polymerase, SEQ ID NO: 6.

12. The DNA polymerase of claim 9 , further including one or more additional amino acid modifications consisting of one or more amino acid substitutions at one or more positions selected from the group consisting of: 365, 370, 371, 372, 481, 507, and 509, and the DNA polymerase exhibits an increased branching ratio and/or increased nucleotide binding affinity relative to a reference modified polymerase of SEQ ID NO: 7.

13. The DNA polymerase of claim 9 , further including one or more additional amino acid modifications consisting of an amino acid substitution at position 380, and the DNA polymerase exhibits increased t pol value (or decreased k pol value) relative to the unmodified B103 polymerase, SEQ ID NO: 6.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2022
From: HENDRICKS, STEPHEN P.; PHELAN, MICHAEL; PERIS, MARIAN; CHEN, CHENG-YAO; MAZUR, DANIEL; PENG, XINZHAN; CASTILLO, AMY
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 061218/0599 →
Continuity (17)
Continuation 16123104 · Sep 6, 2018
Division 15169854 · Jun 1, 2016
Division 14710160 · May 12, 2015
Continuation 13540935 · Jul 3, 2012
Continuation 12748359 · Mar 26, 2010
Provisional Application 61307356 · Feb 23, 2010
Provisional Application 61299917 · Jan 29, 2010
Provisional Application 61299919 · Jan 29, 2010
Provisional Application 61293616 · Jan 8, 2010
Provisional Application 61293618 · Jan 8, 2010
Provisional Application 61289388 · Dec 22, 2009
Provisional Application 61263974 · Nov 24, 2009
Provisional Application 61245457 · Sep 24, 2009
Provisional Application 61242771 · Sep 15, 2009
Provisional Application 61184770 · Jun 5, 2009
Provisional Application 61164324 · Mar 27, 2009
Related Publication 20230055565A1 · Feb 23, 2023